This comprehensive book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy, as well as anticipated challenges that may arise from its application in daily practice. It begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. The second part deals with the use proteomics in cell signaling. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in many tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy.
Rezensionen / Stimmen
From the reviews:
"This is a comprehensive overview of the current state of knowledge in the area of cancer proteomics . . appropriate for cancer researchers of diverse specialties and clinicians conducting basic or clinical cancer research. . a book that provides a truly comprehensive look at the utility of proteomics from 'bench to bedside.' All chapters are well referenced and of appropriate length, and many contain helpful illustrations. . an excellent book that is appropriate for scientists and clinicians with an interest in cancer proteomics." (John D. Robertson, Doody's Review Service, May, 2008)
"This book . provides the reader with a current perspective and anticipated uses of proteomic strategies in cancer therapy as well as basic cancer research. . the book provides a broad account of the area of cancer proteomics and adequately covers issues relevant to the use of proteomic strategies in clinical research. . The book would be of interest to clinicians and basic cancer researchers . who are already involved in, or who are considering the use of proteomics in their work." (JF Timms, British Journal of Cancer, Vol. 99 (4), 2008)
